Form 4 CorMedix Inc For: 27 September
- Investing.com
Market Positioning | Learn how CorMedix's expanded portfolio and REZZAYO's potential applications strengthen its competitive stance in the pharmaceutical industry |
Financial Outlook | Analyst targets range from $17 to $23, suggesting significant upside potential for CorMedix's stock amid strong revenue growth projections |
DefenCath's Momentum | Delve into DefenCath's market performance, with projected sales of $200-215M and potential expansion into total parenteral nutrition |
Strategic Acquisition | Explore CorMedix's game-changing $300M acquisition of Melinta Therapeutics, set to diversify revenue streams and boost operational synergies |
Metrics to compare | CRMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRMDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.0x | 4.6x | −0.4x | |
PEG Ratio | 0.02 | −0.11 | 0.00 | |
Price / Book | 1.2x | 1.9x | 2.6x | |
Price / LTM Sales | 1.2x | 2.0x | 3.0x | |
Upside (Analyst Target) | 106.6% | 73.4% | 56.4% | |
Fair Value Upside | Unlock | 17.7% | 7.9% | Unlock |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.